Worth reading
46Recurring
Scored from 5 of 6 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
植物抽出物（皮膚免疫制御を目的とする研究対象）
Applicable field (uses covered by this announcement)
皮膚免疫制御、あれ肌・敏感肌研究
Relationship between the counterparty and the company
IVY COSMETICS CORPORATION4918
Relationship with the Company
当社が学会年会で研究発表を行った関係。
Counterparty日本分子生物学会
第48回日本分子生物学会年会の開催団体。その他の概要はNot disclosed。
Registration number and expiry date
特許第7040833号（JAK阻害剤）
Impact on Business Performance
At this time, there is no impact on results for the current fiscal year
The company does not address Contract Value / Offering price.
Source (materials cited by the company)
第48回日本分子生物学会年会
| Item | Details |
|---|---|
| Names of Products / Services Covered | 植物抽出物（皮膚免疫制御を目的とする研究対象） |
| Counterparty | 日本分子生物学会 |
| Counterparty overview | 第48回日本分子生物学会年会の開催団体。その他の概要はNot disclosed。 |
| Relationship with the Company | 当社が学会年会で研究発表を行った関係。 |
| Applicable area | 皮膚免疫制御、あれ肌・敏感肌研究 |
| Registration number and expiry date | 特許第7040833号（JAK阻害剤） |
| Impact on Business Performance | At this time, there is no impact on results for the current fiscal year |
| Source | 第48回日本分子生物学会年会 |
Items this document does not state (10)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocationLocation scaleQuantitative EffectsUsage history
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.会社は、T細胞と周辺組織細胞の炎症性変化に着目し、免疫細胞の過剰な活性化を制御する植物抽出物を探索した結果、複数の植物抽出物を見いだしたため発表したと説明している。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.